ZOMEDICA CORP.

Zomedica posted revenue of $8.8 million in Q1 2026 (up 35% year over year), marking the 21st consecutive quarter of revenue growth. The diagnostics segment was a major contributor, growing 73%, while adjusted non‑GAAP EBITDA loss improved to $2.4 million (vs. $5.7 million). The company held $47.5 million in cash and plans new TRUFORMA assays for Q3/Q4 2026 and PIMS integration by September 2026; the stock rose 17.9%. » More on de.investing.com

Zomedica is integrating its TRUFORMA diagnostics system into Boehringer Ingelheim’s idPPID program to improve detection and monitoring of PPID in horses. The partnership allows veterinarians to run rapid on‑site tests for equine endogenous ACTH and insulin; Boehringer will reimburse costs for diagnostic tests and provide TRUFORMA devices to clinics free of charge. The agreement expands Zomedica’s installed base, enables reorders of cartridges (including cortisol and progesterone), and is intended to complement Boehringer’s test offerings. Zomedica reported $32 million in revenue in 2025, about $53 million in cash, and 17% revenue growth; however, analysts do not expect profitability in the current year. » More on de.investing.com

Zomedica reported a 16% revenue increase to $8.1 million in Q3 2025, while earnings per share of -$0.01 missed expectations. The company cut operating costs by $2.5 million, grew international sales by 20% and reduced cash burn by 25% compared with 2024. Cash on hand was $54.4 million, and Zomedica is targeting cash-flow break-even by 2027 as well as the market launch of new products. After the results, the stock rose 17.9%, reflecting investor confidence in operational efficiency and growth potential. » More on de.investing.com